These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6840161)

  • 1. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.
    Catalano M; Parini J; Libretti A
    Eur J Clin Pharmacol; 1983; 24(2):157-61. PubMed ID: 6840161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cadralazine in hypertensive patients.
    Leonetti G; Parini J; Visconti M; Gradnik R
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
    Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
    Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive activity of cadralazine in experimental hypertensive rats.
    Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
    Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
    Catalano M; Parini J; Romano M; Libretti A
    Eur J Clin Pharmacol; 1985; 28(2):135-8. PubMed ID: 3886402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
    Buoninconti R; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Eur J Clin Pharmacol; 1986; 30(2):145-50. PubMed ID: 3709638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
    Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    McTavish D; Young RA; Clissold SP
    Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
    Brunel P; Lecaillon JB; Guyene TT; Imhof P; Ménard J
    Br J Clin Pharmacol; 1990 May; 29(5):503-9. PubMed ID: 2190629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.
    Semeraro C; Dorigotti L; Banfi S; Carpi C
    J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
    Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and renal hemodynamic effects of single oral doses of cadralazine and long term antihypertensive effects of cadralazine in patients receiving therapy with beta-blockers and diuretics.
    Persson B; Granerus G; Hedner T; Wysocki M; Andersson O
    Acta Med Scand Suppl; 1986; 714():177-82. PubMed ID: 2883832
    [No Abstract]   [Full Text] [Related]  

  • 15. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study.
    Voto LS; Lapidus AM; Catuzzi P; Uranga Imaz F; Zin C; Margulies M
    Hypertension; 1992 Feb; 19(2 Suppl):II132-6. PubMed ID: 1735567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers.
    Brunel P; Guyene TT; Howald H; Ménard J
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):175-81. PubMed ID: 1717776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
    Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
    Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of a pyridopyridazine as a drug with marked antihypertensive properties (author's transl)].
    Lehmann HU; Witt E; Hochrein H
    Med Klin; 1977 Jul; 72(28-29):1203-8. PubMed ID: 887046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
    Antonicelli R; Savonitto S; Tomassini PF; Gambini C; Sardina M; Paciaroni E
    Int J Clin Pharmacol Ther; 1994 Apr; 32(4):198-203. PubMed ID: 8032580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.
    Caponnetto S; Valvo E; Mocarelli P; Alberti D; Savonitto S
    Eur J Clin Pharmacol; 1991; 40(5):461-5. PubMed ID: 1679390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.